Merck, Amgen's falling profits still beat Street

Earnings season continues with a couple of biggies: Merck unveiled profits that suffered from merger-and-restructuring charges, and Amgen reported street-beating earnings despite some sales declines. Meanwhile, two Japanese drugmakers posted mixed results. Here are the highlights:

  • Merck reported a 52 percent decline in second-quarter profit, as merger-related and restructuring costs more than offset a near doubling in sales as a result of its takeover of Schering-Plough. But without those one-time charges, profits actually grew, beating analysts' estimates. The company's biggest drug, Singulair, posted flat sales of $1.26 billion, while the newly-off-patent blood-pressure drugs Cozaar and Hyzaar saw revenues drop 46 percent to $485 million. Merck earnings | Report | Report

  • Amgen posted better-than-expected Q2 earnings, but lost ground on some of its most important drugs. The anemia drug Aranesp lost 13 percent of its sales, which came in at $603 million; Enbrel sales fell two percent to $877 million. But as Reuters points out, investors were looking past this quarter's numbers, counting on the newly launched Prolia to give Amgen a new boost. Amgen earnings | Report | Report

  • Daiichi Sankyo said it might boost its annual outlook after quarterly profit skyrocketed, aided by a turnaround at its Indian subsidiary Ranbaxy Laboratories. Profits grew to $808 million, almost ten times what they were a year earlier. Report

  • Takeda Pharmaceutical took a big hit from the loss of patent protection on the ulcer treatment Prevacid. Profits fell by one-fourth to $1.2 billion, and the company stuck to its lower-than-last-year forecast for 2010. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.